EPHA2 and melanoma: In 2014 and due to the variable response to dasatinib reported in preclinical and clinical studies, Eustace et al. tried to identify predictive biomarkers and could identify a group of melanoma with high SRC, ANXA1, CAV-1, and EphA2 expression, which are more likely to benefit from dasatinib (Table 1) [62].